Drug Profile
Research programme: tuberculosis therapies - ChemDiv/Chemical Diversity Research Institute
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ChemDiv; Chemical Diversity Research Institute; Novartis Institute for Tropical Diseases
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in Russia
- 04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in Singapore
- 06 Oct 2011 Chemical Diversity Research Institute enters collaboration and License Option Agreement with Novartis Institute for Tropical Diseases for this research programme